Medicenna Therapeutics Corp (MDNA) Stock
MDNA is no longer traded. Medicenna Therapeutics Corp was delisted from the Nasdaq in January 2024.
Prices on this page are historical; the last trade was January 3, 2024 at $0.31.
Medicenna Therapeutics Corp stock price history
MDNA final trading statistics
- Final close
- $0.31
- Final trading day
- Jan 3, 2024
- Market cap at delisting
- $21.29M
- Shares outstanding
- 69.64M
- Final 52-week range
- $0.15 – $0.84
- Avg. volume (final 3 mo.)
- 183,764
- All-time high (split-adj.)
- $5.97 · Dec 2020
- All-time low (split-adj.)
- $0.16 · Nov 2023
- Return since IPO
- -79.6%
- Beta
- 0.77
- Book value / share
- $0.39
- Price / book
- 0.79
Medicenna Therapeutics Corp annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | $1.5M | -$0.19 |
| FY2022 | $0.00 | -$22.6M | -$0.42 |
| FY2021 | $0.00 | -$17.2M | -$0.30 |
| FY2020 | $0.00 | -$8.3M | -$0.24 |
| FY2019 | $0.00 | -$4.7M | -$0.14 |
Last five fiscal years reported before the delisting; fiscal year ending March. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Medicenna Therapeutics Corp stock FAQ
What happened to Medicenna Therapeutics Corp stock?
Medicenna Therapeutics Corp stock was delisted from the Nasdaq. Its final close was $0.31 on January 3, 2024.
Is MDNA stock still trading?
No. MDNA was delisted from the Nasdaq in January 2024 and no longer trades on a U.S. exchange.
What was the last price of MDNA stock?
MDNA closed at $0.31 on its final trading day, January 3, 2024, for a market value of about $21.29M.
What were Medicenna Therapeutics Corp's revenue and earnings in its last full fiscal year?
Medicenna Therapeutics Corp reported revenue of $0.00 and net income of $1.5M in fiscal 2023, its last full year as a public company.
When did Medicenna Therapeutics Corp go public?
Medicenna Therapeutics Corp stock began trading on August 27, 2001.